Cel Sci (CVM) Capital Leases (2012 - 2026)
Cel Sci (CVM) posted Capital Leases of $4.4 million for Q1 2026, down 12.55% sequentially from $5.1 million in Q4 2025, and down 35.29% YoY from $6.8 million in Q1 2025.
Cel Sci (CVM) Capital Leases (2012 - 2026) Analysis & Trends
Cel Sci has reported Capital Leases for 10 years, with the latest figure at $4.4 million in Q1 2026.
- Quarterly Capital Leases fell 35.29% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (down 35.29% YoY) and the FY2025 annual result came in at $5.7 million, down 28.57% from the prior year.
- Capital Leases fell to $4.4 million in Q1 2026 per CVM's latest filing, from $5.1 million in the prior quarter.
- Over five years, Capital Leases peaked at $12.5 million in Q1 2022 and troughed at $4.4 million in Q1 2026.
- A 5-year average of $8.8 million and a median of $9.0 million in 2024 frame the typical range for Capital Leases.
- The sharpest annual moves came in 2022 and 2026: Capital Leases rose 3.65% in 2022, then sank 35.29% in 2026.
- Over 5 years, Capital Leases stood at $11.3 million in 2022, then declined by 16.18% to $9.5 million in 2023, then declined by 21.71% to $7.4 million in 2024, then sank by 31.63% to $5.1 million in 2025, then declined by 12.55% to $4.4 million in 2026.
- According to Business Quant data, Capital Leases over the past three periods registered $4.4 million, $5.1 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.43 Mn |
| Dec 31, 2025 | 5.07 Mn |
| Sep 30, 2025 | 5.68 Mn |
| Jun 30, 2025 | 6.27 Mn |
| Mar 31, 2025 | 6.85 Mn |
| Dec 31, 2024 | 7.41 Mn |
| Sep 30, 2024 | 7.96 Mn |
| Jun 30, 2024 | 8.48 Mn |
| Mar 31, 2024 | 8.99 Mn |
| Dec 31, 2023 | 9.47 Mn |
| Sep 30, 2023 | 9.95 Mn |
| Jun 30, 2023 | 10.41 Mn |
| Mar 31, 2023 | 10.86 Mn |
| Dec 31, 2022 | 11.30 Mn |
| Sep 30, 2022 | 11.72 Mn |
| Jun 30, 2022 | 12.12 Mn |
| Mar 31, 2022 | 12.49 Mn |
| Dec 31, 2021 | 12.88 Mn |
| Sep 30, 2021 | 13.25 Mn |
| Jun 30, 2021 | 13.60 Mn |